Offshore generics makers eye biosimilars

Chinese and Indian generics makers say they are on the verge of selling cheaper copies of complex biotech medicines. They may enter the market as soon as next year, thanks to huge investments in biotech plants. The New York Times anticipates a transformation of care for patients in much of the world in addition to a counterattack by Big Pharma. Story

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.